HomeSLN • NASDAQ
Silence Therapeutics PLC - ADR
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 25.55M | 1,180.58% |
Operating expense | 16.51M | 144.71% |
Net income | 10.34M | 159.17% |
Net profit margin | 40.47 | 104.62% |
Earnings per share | — | — |
EBITDA | 6.92M | 214.46% |
Effective tax rate | 46.54% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 147.33M | 114.18% |
Total assets | 202.64M | 69.64% |
Total liabilities | 68.61M | -29.60% |
Total equity | 134.02M | — |
Shares outstanding | 47.22M | — |
Price to book | 0.96 | — |
Return on assets | 8.17% | — |
Return on capital | 13.41% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 10.34M | 159.17% |
Cash from operations | -27.62M | -91.10% |
Cash from investing | 62.32M | 5,532.17% |
Cash from financing | 1.40M | -88.85% |
Net change in cash | 42.62M | 1,757.25% |
Free cash flow | -2.14M | -67.96% |
Previous close
$2.74
Day range
$2.39 - $2.74
Year range
$2.37 - $24.38
Market cap
123.26M USD
Avg Volume
208.92K
Primary exchange
NASDAQ
About
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London. Wikipedia
Founded
1994
Website
Employees
116
